Hara Capital’s Novo Nordisk NVO Stock Holding History

Hara Capital’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.59M	Buy	94,674 +24,720	+35%	+$1.17M	1.79%	13
2025 Q4	$3.56M	Buy	69,954 +23,537	+51%	+$1.2M	1.98%	11
2025 Q3	$2.58M	Buy	+46,417	New	+$2.72M	1.52%	17

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Hara Capital's NVO Position: Q1 2026 in Review

Hara Capital increased its Novo Nordisk (NVO) stake by 35% in Q1 2026, buying an estimated $1.17M and bringing the position to 94,674 shares worth $3.59M. The position accounts for 1.79% of the portfolio, ranked #13.

Hara Capital first reported a position in NVO in Q3 2025 and has held it in 3 quarters since. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Hara Capital held 94,674 shares of Novo Nordisk worth $3.59M as of Q1 2026.
Hara Capital bought 24,720 Novo Nordisk shares in Q1 2026, an estimated $1.17M.
Novo Nordisk made up 1.79% of Hara Capital's portfolio in Q1 2026, its #13 holding.
Hara Capital first reported a position in Novo Nordisk in Q3 2025 and has held it in 3 quarters since.
1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Hara Capital's 13F filing for Q1 2026, filed 14 May 2026.